FUNCTIONAL ACTIVITIES OF 20 HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1)-SPECIFIC HUMAN MONOCLONAL-ANTIBODIES

Antibodies that are useful in the treatment of HIV infection should re sult in virus neutralization or lysis of infected cells but should not enhance infection, In this study, the potential clinical use of 20 HI V-1-specific human monoclonal antibodies (HuMAbs) was determined by me asuring their neutralizing, antibody-dependent cellular cytotoxicity ( ADCC), and complement-mediated antibody-dependent enhancing (C-ADE) ac tivities using HIVLAI as the target virus, Two HuMAbs mediated both C- ADE and ADCC, two exclusively neutralized, and five exclusively mediat ed ADCC, Ten HuMAbs demonstrated no activity in any of the three assay s, Three antibodies that neutralized HIVLAI were tested against HIVSF2 ; all three also neutralized HIVSF2, Four of five HuMAbs mediating ADC C against HIVLAI that were also tested against HIVSF2 had ADCC activit y against HIVSF2, These results demonstrate that many HuMAbs have uniq ue functions, allowing tbe separation of potentially beneficial and ha rmful activities. Combinations of HuMAbs with ADCC and neutralizing fu nctions may have therapeutic utility.